Views

CrossRef citations to date

Altmetric

Original Articles: Clinical

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Matthew D. SeftelDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Correspondence[email protected]

John KuruvillaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Tom KouroukisDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;

Versha BanerjiDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;

Graeme FraserDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;

Michael CrumpDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Rajat KumarDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;

Haji I. ChalchalDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;

Muhammad SalimDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;

Rob C. LaisterDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Susan CrockerDepartment of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada;

Spencer B. GibsonResearch Institute of Oncology and Hematology, CancerCare Manitoba and Department of Biochemistry, University of Manitoba, Winnipeg, MB, Canada;

Marcia ToguchiAstex Pharmaceuticals, Cambridge, UK;

John F. LyonsAstex Pharmaceuticals, Cambridge, UK;

Hao XuCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Jean PowersCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Joana SederiasCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Lesley SeymourCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Annette E. HayCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada; ;Department of Medicine, Queen’s University, Kingston, ON, Canada

show all

Abstract

AT7519M is a small molecule inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies. In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m² twice weekly for 2 of every 3 weeks. Primary objective was objective response rate (ORR). Nineteen patients were accrued (7 CLL, 12 MCL). Four CLL patients achieved stable disease (SD). Two MCL patients achieved partial response (PR), and 6 had SD. One additional MCL patient with SD subsequently achieved PR 9 months after completion of AT7519M. Tumor lysis syndrome was not reported. In conclusion, AT7519M was safely administered to patients with relapsed/refractory CLL and MCL. In CLL, some patients had tumor reductions, but the ORR was low. In MCL, activity was noted with ORR of 27%.

Keywords:

Acknowledgements

The authors would like to thank the patients and clinical trials support staff at all participating sites. The Canadian Cancer Trials Group (CCTG) is supported by a grant from the Canadian Cancer Society. Astex Pharmaceuticals provided funding to support this trial.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http://dx.doi.org/10.1080/10428194.2016.1239259.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Information for

Open access

Opportunities

Help and information

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Abstract

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature